Background and Purpose— Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence from …

… Oral anticoagulants such as apixaban, dabigatran, and … indirect comparison meta-analysis
between new oral agents … parameters may exist between oral anticoagulant agents in patients …

Full article: Comparison of major bleeding risk in patients with non-valvular atrial fibrillation
receiving direct oral anticoagulants in the real-world setting: a network meta-analysis Skip to …

… Reasons behind the better persistence with warfarin or apixaban compared to rivaroxaban
or dabigatran treatment in our real-life setting are not known but differences in tolerability may …

… a range of representative care settings in each participating … of the different care settings in
each participating country (office-… with DTI and FXaI in comparison with VKAs are consistent …

Purpose Three new oral anticoagulants (NOACs) have recently become available in the United
Kingdom as an alternative to warfarin in the prevention of stroke and systemic embolism …

… Different from warfarin, novel oral anticoagulants (NOACs) … Although direct or indirect
comparisons between NOACs have … the most favourable oral anticoagulation for Asian patients. …

… To date, none of the published randomized, controlled trials comparing clinical outcomes
of oral anticoagulant treatment in these 2 settings has reported such a difference (14-17). …

… Results & conclusion: In comparison with vitamin K antagonists, apixaban, dabigatran and
… oral anticoagulants for the treatment of non-valvular atrial fibrillation in real-world settings, …

… anticoagulant drugs. To facilitate a direct comparison between new users of direct oral
anticoagulants … were excluded if they had any anticoagulant prescription in the last 12 months …